Fudan University: Stomach Neoplasms trials

The registry lists 56 Stomach Neoplasms studies with Fudan University as lead sponsor. 25 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 34Phase 3 9No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingNCT07874425Phase 2
• Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric CancerRecruitingNCT07517107Phase 2
• Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07515625Phase 2
• Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07507916Phase 2
• A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07492615Phase 2
• The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut MicrobiotaRecruitingNCT07400354
• Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ AdenocarcinomaRecruitingNCT07389876
• Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Phase 2
• Prospective Gastric Cancer Screening With Fecal Multi-target DNA AnalysisRecruitingNCT06943807
• Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialNot yet recruitingNCT06943794Not applicable
• Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes TestNot yet recruitingNCT06943768
• An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter PyloriRecruitingNCT06896370
• The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric CancerRecruitingNCT06786169
• Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric CancerNot yet recruitingNCT06748508Phase 2
• Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled TrialNot yet recruitingNCT06468969Not applicable
• Metronomic Capecitabine in Stage III Gastric CancerRecruitingNCT06313567Phase 3
• Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaRecruitingNCT06228963Phase 2
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2
• Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGCRecruitingNCT05982834Phase 1/2
• Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric CancerRecruitingNCT05982301Phase 2
• Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric CancerRecruitingNCT05975749Phase 2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
• Laparoscopic vs Open Total Gastrectomy for Gastric CancerRecruitingNCT05537129Not applicable
• Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric CancerRecruitingNCT04809025
• S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）RecruitingNCT03941561Phase 3
• Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric CancerActive, not recruitingNCT07312500
• Recurrence and Prognosis Prediction Model for Gastric CancerCompletedNCT07243847
• Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06914687Phase 2
• Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Phase 2
• Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric CancerCompletedNCT05541783Not applicable
• PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingNCT05468138Phase 2
• Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric CancerTerminatedNCT05161572Phase 2
• Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
• Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05095636Phase 2
• Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 TrialCompletedNCT04510064Phase 2
• The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric CancerStatus unknownNCT03889626Phase 3
• A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant AscitesStatus unknownNCT03475615Phase 3
• XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Phase 3
• Peritoneal Lavage for Early Detecting Gene Mutation of Peritoneal Metastasis of Gastric CancerCompletedNCT03314649
• The Maintenance Treatment of UFT in Advanced Gastric CancerCompletedNCT02903498Phase 2
• The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant AscitesStatus unknownNCT02779608Phase 2
• Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.WithdrawnNCT02736552Phase 3
• Irinotecan as 3rd Line Therapy in Gastric CancerStatus unknownNCT02662959Phase 2
• The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric CancerCompletedNCT02395640Phase 3
• Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric CancerStatus unknownNCT02072317Phase 2
• Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric CarcinomaStatus unknownNCT02024217Phase 2
• A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGCStatus unknownNCT01963702Phase 2
• Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total GastrectomyStatus unknownNCT01697943Phase 3
• Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric CancerStatus unknownNCT00992199Phase 2
• Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric CancerCompletedNCT00970138Phase 2/3
• Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGCCompletedNCT00767377Phase 2
• Study of Cetuximab to Treat Gastric CancerCompletedNCT00699881Phase 2
• Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerTerminatedNCT00595985Phase 2
• Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric CancerCompletedNCT00595972Phase 2
• Study of Weekly DCF to Treat Advanced Gastric CancerTerminatedNCT00568971Phase 2
• Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric CancerSuspendedNCT00568529Phase 2